Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives.
Animals
Antineoplastic Agents, Immunological
/ pharmacology
Biliary Tract Neoplasms
/ diagnosis
Biomarkers, Tumor
Clinical Trials as Topic
Combined Modality Therapy
/ methods
Disease Management
Disease Susceptibility
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Molecular Targeted Therapy
/ methods
Precision Medicine
/ methods
Prognosis
Treatment Outcome
biliary tract cancer
immunotherapy
precision medicine
target therapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Jan 2022
13 Jan 2022
Historique:
received:
31
12
2021
revised:
09
01
2022
accepted:
11
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
4
2
2022
Statut:
epublish
Résumé
Biliary tract cancers (BTC) represent a heterogeneous and aggressive group of tumors with dismal prognosis. For a long time, BTC has been considered an orphan disease with very limited therapeutic options. In recent years a better understanding of the complex molecular landscape of biology is rapidly changing the therapeutic armamentarium. However, while 40-50% of patients there are molecular drivers susceptible to target therapy, for the remaining population new therapeutic options represent an unsatisfied clinical need. The role of immunotherapy in the continuum of treatment of patients with BTC is still debated. Despite initial signs of antitumor-activity, single-agent immune checkpoint inhibitors (ICIs) demonstrated limited efficacy in an unselected population. Therefore, identifying the best partner to combine ICIs and predictive biomarkers represents a key challenge to optimize the efficacy of immunotherapy. This review provides a critical analysis of completed trials, with an eye on future perspectives and possible biomarkers of response.
Identifiants
pubmed: 35055006
pii: ijms23020820
doi: 10.3390/ijms23020820
pmc: PMC8775359
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Nat Genet. 2015 Sep;47(9):1003-10
pubmed: 26258846
N Engl J Med. 2020 Dec 3;383(23):2207-2218
pubmed: 33264544
Lancet Oncol. 2021 Sep;22(9):1290-1300
pubmed: 34339623
Ann Oncol. 2020 Oct;31(10):1405-1412
pubmed: 32622884
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Lancet Oncol. 2020 Jun;21(6):796-807
pubmed: 32416072
Int J Cancer. 2020 Oct 15;147(8):2190-2198
pubmed: 32359091
Cancers (Basel). 2021 Mar 29;13(7):
pubmed: 33805461
Clin Cancer Res. 2019 May 1;25(9):2699-2707
pubmed: 30745300
Ann Oncol. 2020 Oct;31(10):1336-1349
pubmed: 32710930
Am J Pathol. 2010 Jul;177(1):141-52
pubmed: 20489148
JAMA Oncol. 2021 Nov 1;7(11):1669-1677
pubmed: 34554208
J Clin Med. 2019 Dec 29;9(1):
pubmed: 31905724
Hepatology. 2021 Jan;73 Suppl 1:75-85
pubmed: 32500550
N Engl J Med. 2021 Apr 8;384(14):1289-1300
pubmed: 33616314
Cancer Lett. 2018 Dec 1;438:17-23
pubmed: 30217563
Cancer Biother Radiopharm. 2012 Feb;27(1):23-35
pubmed: 22316209
Genome Med. 2020 Jan 14;12(1):8
pubmed: 31937368
J Clin Oncol. 2018 Jan 20;36(3):276-282
pubmed: 29182496
Front Pharmacol. 2020 May 15;11:722
pubmed: 32528284
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461347
Liver Int. 2019 May;39 Suppl 1:63-78
pubmed: 30907492
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
Int J Cancer. 2021 Dec 1;149(11):1944-1954
pubmed: 34309846
Cancer Cell Int. 2020 Jan 13;20:16
pubmed: 31956294
Ann Oncol. 2009 Jan;20(1):146-59
pubmed: 18667395
Semin Radiat Oncol. 2015 Jan;25(1):11-7
pubmed: 25481261
JAMA Oncol. 2020 Sep 1;6(9):1405-1409
pubmed: 32729929
Lancet Oncol. 2020 Feb;21(2):271-282
pubmed: 31838007
Expert Opin Investig Drugs. 2021 Apr;30(4):351-363
pubmed: 33382361
Lancet Oncol. 2019 May;20(5):663-673
pubmed: 30922733
Front Immunol. 2017 Aug 02;8:829
pubmed: 28824608
Int Rev Cell Mol Biol. 2017;330:295-342
pubmed: 28215534
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Oncologist. 2018 Dec;23(12):1407-e136
pubmed: 29853658
Cancer Treat Rev. 2020 Jun;86:102019
pubmed: 32251926
Cancer Treat Rev. 2019 Jun;76:22-32
pubmed: 31079031
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32487569
Future Oncol. 2020 Oct;16(30):2385-2399
pubmed: 32677452
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Lancet Oncol. 2020 May;21(5):671-684
pubmed: 32203698
Ann Oncol. 2021 Sep;32(9):1111-1126
pubmed: 33932504
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
JAMA Oncol. 2020 Jun 1;6(6):888-894
pubmed: 32352498
J Gastrointest Oncol. 2019 Aug;10(4):652-662
pubmed: 31392046
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Mol Cancer Ther. 2015 Apr;14(4):847-56
pubmed: 25695955
Semin Cancer Biol. 2021 Aug 10;:
pubmed: 34389490
Cancer Discov. 2017 Oct;7(10):1116-1135
pubmed: 28667006
Cancer Discov. 2021 Feb;11(2):326-339
pubmed: 33218975
Cancers (Basel). 2020 May 14;12(5):
pubmed: 32423017
JAMA Oncol. 2021 Jun 1;7(6):895-902
pubmed: 33792646
Cancers (Basel). 2020 Jul 24;12(8):
pubmed: 32722188
Cancer. 2020 Jun 1;126(11):2666-2678
pubmed: 32129902
JAMA Surg. 2014 Jun;149(6):565-74
pubmed: 24718873
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Cancer Discov. 2015 Jan;5(1):16-8
pubmed: 25583798
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Br J Cancer. 2019 Jan;120(2):165-171
pubmed: 30420614
Cancer Cell. 2015 Dec 14;28(6):690-714
pubmed: 26678337
Br J Cancer. 2010 Jan 5;102(1):115-23
pubmed: 19997099
Angiogenesis. 2014 Jul;17(3):471-94
pubmed: 24482243
Cancers (Basel). 2021 Oct 15;13(20):
pubmed: 34680318
JAMA Oncol. 2020 Nov 1;6(11):1766-1772
pubmed: 33001143
Lancet Oncol. 2020 Sep;21(9):1234-1243
pubmed: 32818466
Lancet. 2021 Jan 30;397(10272):428-444
pubmed: 33516341
Clin Cancer Res. 2018 Sep 1;24(17):4154-4161
pubmed: 29848569
Oncoimmunology. 2020 Jan 9;9(1):1703449
pubmed: 32002302
Lancet Oncol. 2019 Aug;20(8):1109-1123
pubmed: 31301962
Future Oncol. 2020 Oct;16(30):2375-2384
pubmed: 32580579
Hum Pathol. 2014 Aug;45(8):1630-8
pubmed: 24837095
Eur J Cancer. 2021 Jan;143:55-63
pubmed: 33279854
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Cancers (Basel). 2021 Sep 21;13(18):
pubmed: 34572944
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Cancer Treat Rev. 2021 Apr;95:102170
pubmed: 33735689
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Clin Cancer Res. 2014 Nov 1;20(21):5384-91
pubmed: 25204552
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33172881
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):611-621
pubmed: 31109808